Vividion Publishes Preclinical Data in Science on Novel RAS-PI3K Inhibitors Blocking Tumor Growth

Vividion Publishes Groundbreaking Science Study on Covalent RAS-PI3Kα Inhibitors That Halt Tumor Growth Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company and wholly owned, independently operated subsidiary of Bayer AG,…

Read MoreVividion Publishes Preclinical Data in Science on Novel RAS-PI3K Inhibitors Blocking Tumor Growth

Eikonizo Highlights HDAC6 Inhibitors’ Disease-Modifying Potential in ALS and FTD

Eikonizo Therapeutics Highlights Breakthrough Preclinical Findings Demonstrating the Disease-Modifying Potential of Selective HDAC6 Inhibitors in ALS and FTD Eikonizo Therapeutics, a biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative…

Read MoreEikonizo Highlights HDAC6 Inhibitors’ Disease-Modifying Potential in ALS and FTD